Group of anti-diabetic drugs can significantly lower cancer risk in women with type 2 diabetes

December 6, 2013

A Cleveland Clinic-led study shows that a specific type of diabetes drug can decrease the risk of cancer in female patients with type 2 diabetes by up to 32 percent.

People with type 2 diabetes have a higher rate of and compared to the . This study – published online today by the journal Diabetes, Obesity and Metabolism – shows that widely prescribed anti-diabetes drugs can be linked to either an increased or decreased risk of cancer, depending on the type of medication prescribed.

A team of researchers led by Sangeeta Kashyap, M.D., an and associate professor of medicine at Cleveland Clinic's Endocrinology & Metabolism Institute, compared two groups of drugs commonly used to treat type 2 diabetes – insulin sensitizers and insulin secretagogues. Insulin sensitizers lower blood sugar and insulin levels in the body by increasing the muscle, fat and liver's response to insulin. Insulin secretagogues lower blood sugar by stimulating pancreatic beta cells to make more insulin.

"What this study shows us is that using insulin secretagogues to increase insulin production correlates with an increased cancer risk in women with type 2 diabetes," said Kashyap. "By contrast, insulin sensitizers cut insulin levels and can decrease cancer growth. So, clearly, when prescribing anti-diabetic medications, it's important to consider the impact a drug has on fueling cancer growth."

In a retrospective analysis, researchers cross-indexed the electronic health record-based Cleveland Clinic Diabetes Registry (25,613 patients) with the histology-based tumor registry (48,051 cancer occurrences) over an 8-year period (1998–2006). More than 890 incident cancer cases were identified. The two most common cancers were prostate and breast, accounting for more than 25 percent of total cancer cases.

Study results show that the use of insulin sensitizers in with type 2 diabetes was associated with a 21 percent decreased cancer risk compared with insulin secretagogues. Furthermore, the use of a specific insulin sensitizer, thiazolidinedione, was associated with a 32 percent decreased cancer risk in female patients compared with sulphonylurea, an insulin secretagogue. Results showed no significant difference in men.

The findings in this study contribute to existing research in the field on diabetic patients and their increased cancer risk. Further research is needed to examine the impact of oral diabetes therapy on cancer risk and development.

Explore further: No link found between various insulins and breast cancer

Related Stories

No link found between various insulins and breast cancer

September 3, 2013
(HealthDay)—Various types of insulins are not associated with breast cancer risk, according to a study published online Aug. 15 in Diabetes Care.

Cancer prevalence higher with long duration of diabetes

January 24, 2013
(HealthDay)—Patients diagnosed with type 2 diabetes have a greater prevalence of cancer with longer diabetes duration and with insulin use, according to a study published online Jan. 8 in Diabetes Care.

No increased cancer risk with glargine versus human insulin

August 6, 2013
(HealthDay)—There is no evidence that patients with diabetes who initiate insulin glargine have a higher risk of cancer than similar patients initiating human neutral protamine Hagedorn (NPH) insulin, according to a study ...

Risk of hospitalized fall injury up for seniors with diabetes

November 20, 2013
(HealthDay)—Older adults with diabetes, especially those treated with insulin, are at increased risk of injurious falls requiring hospitalization, according to a study published online Oct. 15 in Diabetes Care.

Insulin degludec lowers risk of recurrent low blood sugar or has similar risk to insulin glargine

June 18, 2013
Insulin degludec (Tresiba), a new ultra-long-acting insulin, has a similar or reduced risk of recurrent hypoglycemia— low blood sugar— compared with the commercially available insulin glargine, a new meta-analysis study ...

Diabetes linked to lung cancer in postmenopausal women

May 30, 2012
(HealthDay) -- Postmenopausal women with diabetes are at a significantly higher risk of developing lung cancer, particularly if they require insulin therapy, according to research published online May 22 in Diabetes Care.

Recommended for you

Alzheimer's drug cuts hallmark inflammation related to metabolic syndrome by 25 percent

July 20, 2017
An existing Alzheimer's medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the ...

Diabetes or its precursor affects 100 million Americans

July 19, 2017
Almost one-third of the US population—100 million people—either has diabetes or its precursor condition, known as pre-diabetes, said a government report Tuesday.

One virus may protect against type 1 diabetes, others may increase risk

July 11, 2017
Doctors can't predict who will develop type 1 diabetes, a chronic autoimmune disease in which the immune system destroys the cells needed to control blood-sugar levels, requiring daily insulin injections and continual monitoring.

Diabetes complications are a risk factor for repeat hospitalizations, study shows

July 7, 2017
For patients with diabetes, one reason for hospitalization and unplanned hospital readmission is severe dysglycemia (uncontrolled hyperglycemia - high blood sugar, or hypoglycemia - low blood sugar), says new research published ...

Researchers identify promising target to protect bone in patients with diabetes

July 7, 2017
Utilizing metabolomics research techniques, NYU Dentistry researchers investigated the underlying biochemical activity and signaling within the bone marrow of hyperglycemic mice with hopes of reducing fracture risks of diabetics

Immune system killer cells increase risk of diabetes

July 6, 2017
More than half of the German population is obese. One effect of obesity is to chronically activate the immune system, placing it under continuous stress. Researchers in Jens Brüning's team at the Max-Planck-Institute for ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.